Navigation Links
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
Date:8/27/2008

SAN DIEGO, Aug. 27 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder will present the company's corporate overview on Thursday, September 4 at 4:00pm Eastern Time (1:00pm Pacific Time) during the 2008 NewsMakers In the Biotech Industry Conference at the Millennium Broadway Hotel in New York City.

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at http://www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcast and will be archived for 90 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.

Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence

Pharmaceuticals, Inc.

Contacts:

William R. LaRue Anna Gral
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
2. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIO Investor Forum
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
8. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
9. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014  ImmunoClin Corporation ... personalized medicine, treatment of infectious diseases as well ... prognosis and prevention of pathologies like cardiovascular disease, ... 1, 2014, ImmunoClin Corporation will complete the strategic ... Washington, D.C. , a key center of ...
(Date:7/29/2014)...  Sigma-Aldrich Corporation (NASDAQ: SIAL ) dramatically ... investment in Green Chemistry and donated more than 8,000 ... the Company announced Monday in its new 2013 ... The report comes in a year ... responsible corporate citizen, including recognition for the second consecutive ...
(Date:7/29/2014)... The first product launch from start-up Hurley ... robotics. What sets Droidles completely apart from other stand ... them to communicate, share code with each other and ... “The invention is the system,” said Hurley Research founder ... of their own, both physically and on the internet." ...
(Date:7/29/2014)... Acres, FL (PRWEB) July 29, 2014 ... ex situ lift out specimen preparation solutions, has been ... Trademark Office for specimen manipulation methods incorporating a unique ... 8,740,209. This is the second company patent for ... A. Giannuzzi. , These complementary patents extend ...
Breaking Biology Technology:ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 2ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 3Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3Droidles, the Social Network of Robots and Open Source Platform for the Internet of Things, Launches for Crowd Funding on IndieGoGo.com 2EXpressLO LLC Granted Second U.S. Patent for Innovative Specimen Preparation Methods 2
... Research Foundation has licensed the California immunological research ... WARF's stem cell patents, Chemicon's parent company Serologicals ... to WARF's portfolio of stem cell technologies, which were ... . , ,Jeff Linton, president of Chemicon, said ...
... Platypus Technologies of suburban Madison has received ... for $200,000 from the National Cancer Institute. The grant ... rapid quantification of protein activity, useful for cancer research. ... II SBIR grant for $2.14 million from the National ...
... Customer Potential Management , a developer of databases and ... management solution has been implemented at the Michigan hospital ... the CRM solution to promote its collaboration with the ... with oncologists from both hospitals. While market research said ...
Cached Biology Technology:WARF signs stem cell agreement with California firm 2
(Date:7/28/2014)... the U.S. Food and Drug Administration (FDA) for other ... pathogens inside human cells, including those that cause Legionnaires, ... in mBio , the online open-access journal of ... of identifying non-antibiotic drugs that could one day help ... on the list inhibit the growth of at least ...
(Date:7/28/2014)... States have a circulatory problem of the legs called ... even require surgery in serious cases. This disease can ... limb amputation. , At The University of Texas Health ... a non-surgical preventative treatment in a mouse model of ... circulation. Their proof-of-concept study appears in the journal ...
(Date:7/28/2014)... rat brain cells suggests that the effects of a ... cells are temporary. , The study, published in this ... was conducted by biologists at the University of California, ... York in response to concerns, arising from multiple studies ... to general anesthetics may increase their susceptibility to long-term ...
Breaking Biology News(10 mins):New route to identify drugs that can fight bacterial infections 2Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 3
... genomics initiative ever undertaken an international effort to ... Earth will be officially activated this week. , ... launched by the Minister of Research and Innovation, Glen ... Saturday, September 25 at 6:30 p.m. , By enabling ...
... Contrary to a thousand face cream adverts, the secret of ... Dr. Carlos Herrera, a Professor of Research at the Consejo ... the withering action of flowers may have evolved to protect ... issue of the Annals of Botany ( http://dx.doi.org/10.1093/aob/mcq160 ...
... objects in a new computer program designed to give people ... thought the ease of the using the program,s automatic mode ... many participants in a pilot study didn,t like it because ... mode, which requires them to think several steps ahead and ...
Cached Biology News:Building a digital library for life on Earth 2Robotic arm's big flaw: Patients say it's 'too easy' 2
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ...
... Maximize the value of your microarray data ... support you need from consultation to extensive ... date methods. Utilize our expertise in combination ... from your own microarray experiments., ,Normalization and ...
BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap. (2/sp, 20/ca) Packaging: 2 / pack, 20 /...
... of Flight Mass Analyzer for superior sensitivity, mass accuracy, and resolving ... m/z, * Precursor ion selection range: 150 - 4000 m/z, * ... with internal reference, * Dynamic range: 4 orders of magnitude ... ...
Biology Products: